ISLAMABAD: The Drug Regulatory Authority of Pakistan (DRAP) has recalled a batch of cough syrup from the market after discovering that it lacks a sufficient amount of essential elements needed for effective treatment.
The regulatory authority issued a product recall alert for 1068 batches of the substandard Chemoderal syrup, a popular oral cough medicine widely available to the general public, doctors, and chemists.
The cough syrup, designed to combat colds and allergies, comprises three key elements crucial for its therapeutic efficacy. However, an alarming deficiency of sodium citrate was detected, potentially rendering the medicine less effective than required. DRAP’s alert emphasizes that consuming the deficient Chemoderal syrup could lead to adverse effects such as stomach discomfort and disrupted sleep patterns.
DRAP’s Swift Action Against Cough Syrup
Manufactured by Aleem Pharmaceuticals located in Hyderabad, the substandard batches were identified by the Central Drug Laboratory in Karachi, prompting immediate action from DRAP. The regulatory authority has not only recalled the affected batches but also issued stringent directives to halt the distribution of these batches in the market. Additionally, chemists have been instructed to return any remaining stock of the cough syrup to the pharmaceutical company.
